Nkarta Therapeutics is a technology company.
Nkarta Therapeutics has raised $110.0M across 1 funding round.
Nkarta Therapeutics has raised $110.0M in total across 1 funding round.
Nkarta Therapeutics is a clinical-stage biopharmaceutical company specializing in engineered allogeneic (off-the-shelf) natural killer (NK) cell therapies aimed primarily at treating cancer and autoimmune diseases. Their proprietary platform enhances NK cells to improve potency, safety, and accessibility, targeting difficult-to-treat hematologic malignancies and autoimmune conditions by providing scalable, ready-to-use cell therapies that overcome limitations of existing autologous CAR-T treatments[1][2][3].
Founded with a mission to transform cancer treatment, Nkarta serves patients, healthcare providers, and the broader medical community by developing innovative cell therapies designed to improve patient outcomes and quality of life. The company is gaining momentum through clinical-stage development and strategic collaborations, positioning itself as a leader in next-generation cell therapy[1][2].
---
Nkarta Therapeutics was founded by a team of scientists and industry experts focused on harnessing the innate cancer-fighting power of natural killer cells. The idea emerged from advances in immunotherapy and cell engineering, aiming to create off-the-shelf NK cell therapies that are safer and more effective than existing options. Early traction came from demonstrating the ability to engineer NK cells with enhanced persistence and targeting capabilities, enabling scalable manufacturing from healthy donor cells and reducing severe side effects common in other cell therapies[1][3].
---
---
Nkarta is riding the wave of immuno-oncology and cell therapy innovation, particularly the shift toward allogeneic, off-the-shelf treatments that promise broader patient access and scalability. The timing is critical as demand grows for safer, more effective cancer and autoimmune therapies with faster delivery timelines. Market forces such as increasing cancer incidence, unmet needs in hematologic malignancies, and advances in genetic engineering favor Nkarta’s approach. By pioneering NK cell therapies, Nkarta influences the broader biotech ecosystem by expanding the therapeutic modalities beyond CAR-T and monoclonal antibodies, potentially setting new standards for cell therapy safety and efficacy[1][2][3].
---
Nkarta’s next phase involves advancing clinical trials to demonstrate efficacy and safety in larger patient populations, potentially leading to regulatory approvals and commercialization. Trends shaping their journey include continued innovation in cell engineering, growing acceptance of allogeneic therapies, and expanding applications beyond oncology into autoimmune diseases. Their influence may evolve as a key player in making cell therapies more accessible and safer, possibly catalyzing broader adoption of NK cell-based treatments in the biotech industry. Nkarta’s mission to revolutionize cancer and autoimmune therapy aligns with a future where off-the-shelf cell therapies become standard care, fulfilling critical unmet medical needs[1][3][4].
Nkarta Therapeutics has raised $110.0M in total across 1 funding round.
Nkarta Therapeutics's investors include Amzak Health Investors, EQT Life Sciences, Morgenthaler Ventures, Ali Behbahani, OrbiMed, Samsara BioCapital, SR One.
Nkarta Therapeutics has raised $110.0M across 1 funding round. Most recently, it raised $110.0M Series B in September 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2019 | $110.0M Series B | Amzak Health Investors, EQT Life Sciences, Morgenthaler Ventures, Ali Behbahani, OrbiMed, Samsara BioCapital, SR One |